Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.74 |
| ▸ | RAB9A | P51151 | 8/20 | 0.67 |
| ▸ | NPC1 | O15118 | 8/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18905578 | 0.86 | RAB9A (0.64) | TDP1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL18905577 | 0.86 | RAB9A (0.64) | TDP1RAB9ANPC1L3MBTL1SMN1; SMN2 | |
| SCHEMBL6023593 | 0.85 | TDP1 (1.00) | TDP1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL31344217 | 0.83 | RAB9A (0.64) | TDP1RAB9ANPC1POLBL3MBTL1 | |
| SCHEMBL4363828 | 0.82 | RAB9A (0.60) | TDP1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL11895627 | 0.79 | RAB9A (0.58) | TDP1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL18905580 | 0.79 | RAB9A (0.76) | TDP1RAB9ANPC1ALDH1A1L3MBTL1 | |
| SCHEMBL20124839 | 0.79 | RAB9A (0.56) | TDP1RAB9ANPC1POLBALDH1A1 | |
| SCHEMBL1867782 | 0.78 | RAB9A (0.60) | TDP1RAB9ANPC1ALDH1A1L3MBTL1 | |
| SCHEMBL11220601 | 0.77 | LMNA (0.85) | RAB9ANPC1POLBALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10340466-B2 | Organic metal compound, organic light-emitting devices employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-07-02 | — | — | US | disclosed |
| US-20170155063-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170155063-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170155065-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-01 | — | — | US | disclosed |
| US-20170155065-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170155063-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | C5, C9, C1S | TDP1 4634/4885RAB9A 2188/4885NPC1 2598/4885 |
| US-10340466-B2 | Organic metal compound, organic light-emitting devices employing the same | OR10J3, C1S, C5 | TDP1 4318/4885RAB9A 874/4885NPC1 2333/4885 |
| US-20170155065-A1 | ORGANIC METAL COMPOUND, ORGANIC LIGHT-EMITTING DEVICES EMPLOYING THE SAME | OR10J3, C1S, C5 | TDP1 4318/4885RAB9A 874/4885NPC1 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.